Upgrade to SI Premium - Free Trial

Form SCHEDULE 13G Altimmune, Inc. Filed by: Deep Track Capital, LP

April 30, 2026 4:00 PM





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Deep Track Capital, LP
Signature:/s/ David Kroin
Name/Title:David Kroin, Managing Member of the General Partner of the Investment Adviser
Date:04/30/2026
Deep Track Biotechnology Master Fund, Ltd.
Signature:/s/ David Kroin
Name/Title:David Kroin, Director
Date:04/30/2026
David Kroin
Signature:/s/ David Kroin
Name/Title:David Kroin
Date:04/30/2026
Deep Track Special Opportunities Fund, LP.
Signature:/s/ David Kroin
Name/Title:David Kroin, Managing Member of the General Partner of the Investment Adviser of Deep Track Special Opportunities Fund, LP
Date:04/30/2026
Exhibit Information

Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of April 30, 2026, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined using 194,366,579 shares, calculated using 194,199,358 Common Stock outstanding as of April 24, 2026, according to the Prospectus filed with the SEC on April 24, 2026 and 167,221 Common Stock that would be converted to Common Stock by the Reporting Person up to the Maximum Percentage. The beneficially owned shares include 10,750,000 Pre-Funded Warrants exercisable to common stock and 30,000,000 Warrants, both, subject to a 9.99% Maximum Percentage exercise limitation. The Issuer shall not effect the exercise of any portion of the Pre-Funded Warrants or Warrants, to the extent that after giving effect to such exercise, the holder collectively would beneficially own in excess of 9.99% (the "Maximum Percentage") of the number of Common Stock outstanding immediately after giving effect to such exercise. Deep Track Capital LP and David Kroin may be deemed to be considered beneficial owners of a combined 19,250,000 Common Stock, 10,750,000 Pre-Funded Warrants and 30,000,000 Warrants subject to the Maximum Percentage exercise limitation. Deep Track Biotechnology Master Fund Ltd. is the beneficial owner of 16,683,333 Common Stock, 9,316,667 Pre-Funded Warrants and 26,000,000 Warrants subject to the Maximum Percentage exercise limitation. Deep Track Special Opportunities Fund LP is the beneficial owner of 2,566,667 Common Stock, 1,433,333 Pre-Funded Warrants and 4,000,000 Warrants subject to the Maximum Percentage exercise limitation. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: April 30, 2026 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin Deep Track Special Opportunities Fund, LP. By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser of Deep Track Special Opportunities Fund, LP

Categories

SEC Filings